Contract Research Organizations
•37 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (37)
| Company | Market Cap | Price |
|---|---|---|
|
TMO
Thermo Fisher Scientific Inc.
Thermo Fisher provides contract research organization services (CRO capabilities) for outsourced drug development.
|
$230.80B |
$621.97
+1.76%
|
|
IQV
IQVIA Holdings Inc.
IQVIA operates as outsourced drug development and clinical research services akin to a CRO.
|
$39.88B |
$241.34
+2.88%
|
|
LH
Labcorp Holdings Inc.
Labcorp functions as aContract Research Organization offering outsourced drug development and regulatory support services.
|
$21.04B |
$261.17
+3.16%
|
|
MEDP
Medpace Holdings, Inc.
Medpace's core business is a specialized full-service CRO delivering Phase I–IV clinical development services.
|
$16.49B |
$610.88
+4.10%
|
|
ICLR
ICON Public Limited Company
Directly describes ICON's outsourced drug development and management services as a Contract Research Organization.
|
$16.31B |
$201.98
+2.23%
|
|
CRL
Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
|
$10.25B |
$216.75
+4.05%
|
|
OLED
Universal Display Corporation
Contract research services via Adesis subsidiary.
|
$5.86B |
$126.76
+2.88%
|
|
RXRX
Recursion Pharmaceuticals, Inc.
Collaborations with pharma partners and outsourced discovery work resemble a CRO-type service model.
|
$1.90B |
$4.59
+5.03%
|
|
AZTA
Azenta, Inc.
Genewiz genomic sequencing and broader SMS/Multiomics services align with Contract Research Organizations.
|
$1.64B |
$36.88
+3.17%
|
|
FTRE
Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
|
$1.50B |
$17.71
+6.59%
|
|
FLGT
Fulgent Genetics, Inc.
Contract Research Organization services for bioPharma.
|
$776.55M |
$25.72
+1.38%
|
|
ABSI
Absci Corporation
Partnership-driven model for drug creation aligns with Contract Research Organizations (CRO)-like outsourced R&D services.
|
$559.21M |
$3.87
+3.34%
|
|
DNA
Ginkgo Bioworks Holdings, Inc.
Contract Research Organizations as a historic and current service model.
|
$525.10M |
$9.34
+5.24%
|
|
CLPT
ClearPoint Neuro, Inc.
Biologics and drug-delivery consulting capabilities (GLP expansion, preclinical support) align with CRO-like outsourced development services.
|
$403.39M |
$15.29
+7.72%
|
|
QTRX
Quanterix Corporation
Offers contract research services via its Accelerator Lab, aligning with CRO-type activities.
|
$298.78M |
$6.51
+1.32%
|
|
LFCR
Lifecore Biomedical, Inc.
Lifecore's development pipeline and development services align with Contract Research Organizations.
|
$288.80M |
$7.95
+1.92%
|
|
ACRS
Aclaris Therapeutics, Inc.
The company reports contract research revenue, indicating provided drug development services.
|
$287.08M |
$2.63
-0.57%
|
|
BNR
Burning Rock Biotech Limited
Biopharma services segment indicates outsourced R&D, clinical testing, and development support.
|
$252.70M |
$20.24
-17.32%
|
|
IMRX
Immuneering Corporation
The company relies on contract research organizations for preclinical/clinical testing and trials.
|
$240.07M |
$6.72
+1.66%
|
|
MXCT
MaxCyte, Inc.
Contract Research Organizations tag reflects MaxCyte's CRO-like gene editing assessment services through SeQure Dx.
|
$164.17M |
$1.55
+0.65%
|
|
FBIO
Fortress Biotech, Inc.
Fortress engages in outsourced development activities and governance across its portfolio, aligning with CRO services.
|
$127.05M |
$4.09
-4.10%
|
|
CSBR
Champions Oncology, Inc.
Company provides outsourced drug development and preclinical/clinical research services to biopharma (CRO-style).
|
$92.52M |
$6.69
-0.30%
|
|
CBUS
Cibus, Inc.
Reported contract research revenue indicates direct R&D services provided to clients alongside platform licensing.
|
$91.66M |
$1.68
+5.66%
|
|
AKYA
Akoya Biosciences, Inc.
Contract Research Organizations alignment due to outsourced lab services and clinical testing capabilities.
|
$64.26M |
$1.29
|
|
ABVC
ABVC BioPharma, Inc.
BioKey provides Contract Research Organization services, including API characterization, formulation development, and regulatory submissions.
|
$55.32M |
$2.26
-3.83%
|
|
BDSX
Biodesix, Inc.
Biodesix's Development Services revenue aligns with CRO-like outsourced diagnostic testing for partners.
|
$45.68M |
$5.99
-3.85%
|
|
RADX
Radiopharm Theranostics Limited
Company provides external development services for others, akin to CRO activities.
|
$33.67M |
$4.80
-5.88%
|
|
VNRX
VolitionRx Limited
Nu.Q Discover provides epigenetic profiling services to drug developers, akin to Contract Research Organizations.
|
$30.14M |
$0.28
-0.43%
|
|
PLUR
Pluri Inc.
Contract research and development services complement CDMO capabilities and scale the pipeline.
|
$24.14M |
$3.05
+3.04%
|
|
NOTV
Inotiv, Inc.
Inotiv operates as a CRO delivering nonclinical drug discovery and development services, aligning with the Contract Research Organizations tag.
|
$19.87M |
$0.63
+8.90%
|
|
BFRG
Bullfrog AI Holdings, Inc. Common Stock
Engages in external collaborations/partnerships to provide AI-driven drug development services, akin to CRO-type engagements.
|
$8.79M |
$0.86
-0.92%
|
|
SEED
Origin Agritech Limited
Origin provides breeding services and collaborative R&D through a service consortium, aligning with Contract Research Organizations.
|
$7.48M |
$1.12
-4.66%
|
|
APM
Aptorum Group Limited
Aptorum plans near-term revenue from biopharma services via the DiamiR merger, aligning with contract research/Development outsourcing.
|
$5.58M |
$1.07
+5.39%
|
|
BUDZ
WEED, Inc.
Sangre AgroTech represents plant genomic research services, akin to contract research and development.
|
$5.44M |
$0.04
|
|
POAI
Predictive Oncology Inc.
Provides outsourced drug discovery services (wet lab, testing, and preclinical support) akin to a CRO.
|
$4.32M |
$5.94
-0.17%
|
|
YBGJ
Yubo International Biotech Limited
Provides outsourced research/testing services and advisory functions (CRO-like capabilities).
|
$2.11M |
$0.01
|
|
ELAB
PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
|
$1.63M |
$3.35
-13.12%
|
Loading company comparison...
Loading industry trends...
Loading research report...
